BioCardia (BCDA) AI Stock Analysis

• Market Cap: $14.01M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -100.00%
• EPS Growth: 58.50%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 10,612,734
• 10 Day Avg. Volume: 282,453
• 30 Day Avg. Volume: 1,147,607
• PEG Ratio: 0.01
• Price to Book (P/B): 7.15
• Price to Sales (P/S): 103.14
• P/FCF Ratio: -0.74
• Enterprise Value/Market Cap: 577.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.83K
• Enterprise Value/Ebitda: -958.75
• 1Y Price Target: $15.50
• Price Target Upside: 1074.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.50 ▲(13.64% Upside)

BioCardia's overall stock score is primarily impacted by its weak financial performance and valuation. Despite positive developments in clinical trials and regulatory progress, the company's ongoing financial challenges and bearish technical indicators weigh heavily on its score.

Positive Factors

Regulatory Progress in Japan

Advancing to formal clinical consultation with PMDA could lead to regulatory approval in Japan, expanding market access and enhancing long-term growth potential.

FDA Breakthrough Designation

This designation underscores the therapy's potential efficacy, accelerating development and potentially improving market positioning in treating ischemic heart failure.

Partnership for Heart 3D Fusion Imaging

The partnership could enhance BioCardia's technological capabilities, potentially leading to innovative product offerings and strengthening its competitive edge.

Negative Factors

Weak Financial Performance

Ongoing financial challenges, including negative margins, indicate instability and a challenging path to profitability, impacting long-term financial health.

High Debt-to-Equity Ratio

High leverage can strain financial flexibility and increase risk, potentially affecting the company's ability to invest in growth opportunities.

Negative Cash Flow

Dependence on external financing for cash flow needs highlights challenges in generating sufficient operating cash, posing risks to financial sustainability.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia generates revenue primarily through the commercialization of its cell therapy products, which involve a combination of direct sales, partnerships with healthcare providers, and collaborations with pharmaceutical companies for clinical trials and product development. The company may also receive funding through grants and investments aimed at advancing its research and development efforts. Key revenue streams include sales of its CardiAMP and CardiALLO systems, as well as potential royalties from licensing agreements and partnerships that allow other entities to utilize its technologies in their own therapeutic developments.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is weak, with significant challenges in profitability and financial stability. The income statement shows negative EBIT and net income margins, while the balance sheet reveals a high debt-to-equity ratio. Cash flow is negative, relying heavily on financing activities.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-4.42M	-4.33M	-7.25M	-7.48M	375.00K	141.00K
EBITDA	-8.44M	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-8.54M	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	6.15M	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	5.29M	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	638.00K	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	3.52M	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	2.63M	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-7.51M	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-7.51M	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-2.00K	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	7.87M	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Positive. The current price of 1.32 is above the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.33, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	49 Neutral	$11.15M	-0.26	-81.97%	―	-46.88%	34.83%
BCDA	46 Neutral	$14.01M	-0.77	-317.47%	―	-100.00%	58.50%
ETHZ	45 Neutral	$92.78M	-0.07	-371.02%	―	―	―
BRTX	44 Neutral	$10.65M	-0.79	-207.73%	―	1.70%	-111.67%
ATON	40 Underperform	$6.94M	-0.01	―	―	―	―
LYRA	40 Underperform	$6.74M	-0.16	-404.48%	―	-59.21%	68.97%

BioCardia Corporate Events

BioCardia Advances CardiAMP Therapy in Japan

On December 16, 2025, BioCardia announced the completion of a third preliminary clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) for its CardiAMP Cell Therapy aimed at treating Heart Failure with Reduced Ejection Fraction (HFrEF). The PMDA has agreed to allow BioCardia to advance to a formal clinical consultation, which could lead to regulatory approval in Japan if the data is deemed sufficient. The CardiAMP Cell Therapy, which uses a patient’s own bone marrow cells, has shown positive outcomes in clinical trials, including improved survival rates and reduced major adverse cardiovascular events. This development could significantly impact BioCardia’s operations and its positioning in the cardiovascular therapeutics market.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Appoints Marvin Slosman to Board of Directors

On December 2, 2025, BioCardia, Inc. announced the appointment of Marvin Slosman to its Board of Directors, effective immediately, with his term expiring at the 2028 Annual Meeting of Shareholders. Mr. Slosman, who is also the CEO of InspireMD, brings extensive experience in interventional cardiology and global market expansion. His appointment follows the completion of Dr. Richard Krasno’s term, who has been instrumental in guiding the company through significant milestones. The company’s Annual Meeting on the same day saw the election of Class III directors and approval of key proposals, including amendments to the 2016 Equity Incentive Plan and ratification of PKF San Diego, LLP as the independent accounting firm.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Appoints New VP of Quality

On November 24, 2025, BioCardia, Inc. announced the appointment of Farhan Shahab as Vice President of Quality. Shahab brings over 25 years of experience in quality management and regulatory roles from various medical and health companies. His expertise is expected to enhance BioCardia’s efforts in commercializing its investigational products, potentially accelerating their market readiness and strengthening the company’s leadership team.

The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Enrolls First Patient in Phase 3 Trial

On November 10, 2025, BioCardia announced the enrollment of the first patient at Henry Ford Health in its Phase 3 CardiAMP HF II clinical trial for ischemic heart failure with reduced ejection fraction. This trial aims to confirm the safety and efficacy of the CardiAMP autologous cell therapy, which previously showed promising results in reducing mortality and improving quality of life for patients. The trial’s success could address significant clinical needs for the approximately 2 million patients in the U.S. and EU suffering from this condition, potentially impacting patient care and the healthcare system.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Advances Phase 3 CardiAMP HF II Trial

On October 30, 2025, BioCardia, Inc. announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the ongoing Phase 3 CardiAMP HF II clinical trial. This trial aims to confirm the safety and efficacy of CardiAMP autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. The study, which involves 250 patients, utilizes a composite primary outcome measure and incorporates advancements in cell population analysis and delivery systems. The enrollment at this prestigious cardiology center is expected to strengthen the trial and potentially broaden the availability of this therapy.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.